<?xml version="1.0" encoding="UTF-8"?>
<sec id="sec014" class="sec">
 <div class="title" xmlns="http://www.w3.org/1999/xhtml">ADMET predictions</div>
 <p xmlns="http://www.w3.org/1999/xhtml">The theoretical prediction of pharmacokinetics in sílico is an approach that is currently used widely in the initial study of the ADMET properties to reduce unnecessary expense in biological assays of compounds with a high probability of pharmacokinetic problems, which saves on time and investment [
  <a rid="pone.0198476.ref050" ref-type="bibr" href="#pone.0198476.ref050">50</a>].
 </p>
 <p xmlns="http://www.w3.org/1999/xhtml">ADMET analysis for the alkaloids produced the same values for the EPIIS, ISOP and PILO optical isomers, which assigned all three the same prediction in 
  <a rid="pone.0198476.t004" ref-type="table" href="#pone.0198476.t004">Table 4</a>. Through analysis of the plasma protein binding property (PPB), similar values were found for the EPI, EPIIS, ISOP, and PILO isomers (63%), with a lower value found for the MAC alkaloid (37%). The results of the penetration potential in the blood–brain barrier (BBB) showed that the compounds have low potential to cross the blood–brain barrier, indicated by values below 0.1 [
  <a rid="pone.0198476.ref051" ref-type="bibr" href="#pone.0198476.ref051">51</a>]; the obtained values were 0.011 (EPI), 0.016 (EPIIS), and 0.992 (MAC), indicating that these compounds were less likely to cause side effects in the central nervous system [
  <a rid="pone.0198476.ref052" ref-type="bibr" href="#pone.0198476.ref052">52</a>].
 </p>
 <div id="pone.0198476.t004" orientation="portrait" position="float" class="table-wrap" xmlns="http://www.w3.org/1999/xhtml">
  <span pub-id-type="doi" class="object-id">10.1371/journal.pone.0198476.t004</span>
  <span class="label">Table 4</span>
  <div class="caption">
   <div class="title">ADMET predictions of the epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine alkaloids.</div>
  </div>
  <div class="alternatives">
   <div id="pone.0198476.t004g" xlink:href="pone.0198476.t004" class="graphic" xmlns:xlink="http://www.w3.org/1999/xlink"/>
   <table frame="hsides" rules="groups">
    <colgroup span="1">
     <col align="left" valign="middle" span="1"/>
     <col align="left" valign="middle" span="1"/>
     <col align="left" valign="middle" span="1"/>
     <col align="left" valign="middle" span="1"/>
    </colgroup>
    <thead>
     <tr>
      <th align="center" rowspan="1" colspan="1">ADMET</th>
      <th align="center" rowspan="1" colspan="1">EPI</th>
      <th align="center" rowspan="1" colspan="1">EPIIS/ISOP/PILO</th>
      <th align="center" rowspan="1" colspan="1">MAC</th>
     </tr>
    </thead>
    <tbody>
     <tr>
      <td align="left" rowspan="1" colspan="1">Plasma protein binding (PPB) (%)</td>
      <td align="center" rowspan="1" colspan="1">63.140757</td>
      <td align="center" rowspan="1" colspan="1">63.940875</td>
      <td align="center" rowspan="1" colspan="1">37.146972</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Blood-brain barrier penetration (BBB) (C, brain/C, blood)</td>
      <td align="center" rowspan="1" colspan="1">0.011675</td>
      <td align="center" rowspan="1" colspan="1">0.0167958</td>
      <td align="center" rowspan="1" colspan="1">0.992212</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Skin Permeability (logKp, cm/h)</td>
      <td align="center" rowspan="1" colspan="1">-3.86369</td>
      <td align="center" rowspan="1" colspan="1">-3.89764</td>
      <td align="center" rowspan="1" colspan="1">-3.0451</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Human intestinal absorption (HIA, %)</td>
      <td align="center" rowspan="1" colspan="1">96.050121</td>
      <td align="center" rowspan="1" colspan="1">96.050121</td>
      <td align="center" rowspan="1" colspan="1">97.523105</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Caco-2 cell Permeability (nm/s)</td>
      <td align="center" rowspan="1" colspan="1">21.8393</td>
      <td align="center" rowspan="1" colspan="1">22.8681</td>
      <td align="center" rowspan="1" colspan="1">27.2895</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">MDCK cell permeability (nm/s)</td>
      <td align="center" rowspan="1" colspan="1">16.0498</td>
      <td align="center" rowspan="1" colspan="1">9.63097</td>
      <td align="center" rowspan="1" colspan="1">15.7929</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">P-glycoprotein inhibition</td>
      <td align="center" rowspan="1" colspan="1">Non</td>
      <td align="center" rowspan="1" colspan="1">Non</td>
      <td align="center" rowspan="1" colspan="1">Non</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Water solubility in buffer (mg/L)</td>
      <td align="center" rowspan="1" colspan="1">23332.8</td>
      <td align="center" rowspan="1" colspan="1">78158.6</td>
      <td align="center" rowspan="1" colspan="1">3810.15</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Pure water solubility (mg/L)</td>
      <td align="center" rowspan="1" colspan="1">8525.04</td>
      <td align="center" rowspan="1" colspan="1">21880</td>
      <td align="center" rowspan="1" colspan="1">110732</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Ames test</td>
      <td align="center" rowspan="1" colspan="1">Mutagen</td>
      <td align="center" rowspan="1" colspan="1">Mutagen</td>
      <td align="center" rowspan="1" colspan="1">Mutagen</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Ames TA100 (+S9)</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Positive</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Ames TA100 (-S9)</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Positive</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Ames TA1535 (+S9)</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Positive</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Ames TA1535 (-S9)</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Positive</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Carcinogenicity (Mouse)</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Carcinogenicity (Rat)</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
      <td align="center" rowspan="1" colspan="1">Negative</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">CYP 2C19 inhibition</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">CYP 2C9 inhibition</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">CYP 2D6 inhibition</td>
      <td align="center" rowspan="1" colspan="1">Non</td>
      <td align="center" rowspan="1" colspan="1">Non</td>
      <td align="center" rowspan="1" colspan="1">Non</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">CYP 2D6 substrate</td>
      <td align="center" rowspan="1" colspan="1">Non</td>
      <td align="center" rowspan="1" colspan="1">Non</td>
      <td align="center" rowspan="1" colspan="1">Weakly</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">CYP 3A4 inhibition</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
      <td align="center" rowspan="1" colspan="1">Inhibitor</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">CYP 3A4 substrate</td>
      <td align="center" rowspan="1" colspan="1">Substrate</td>
      <td align="center" rowspan="1" colspan="1">Substrate</td>
      <td align="center" rowspan="1" colspan="1">Substrate</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Lipinski’s Rule</td>
      <td align="center" rowspan="1" colspan="1">Suitable</td>
      <td align="center" rowspan="1" colspan="1">Suitable</td>
      <td align="center" rowspan="1" colspan="1">Suitable</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">WDI-like Rule</td>
      <td align="center" rowspan="1" colspan="1">Within 90% cutoff</td>
      <td align="center" rowspan="1" colspan="1">Within 90% cutoff</td>
      <td align="center" rowspan="1" colspan="1">Within 90% cutoff</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">Lead-like Rule</td>
      <td align="center" rowspan="1" colspan="1">Binding affinity &gt; 0.1 μM</td>
      <td align="center" rowspan="1" colspan="1">Binding affinity &gt; 0.1 μM</td>
      <td align="center" rowspan="1" colspan="1">Violated</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">CMC-like Rule</td>
      <td align="center" rowspan="1" colspan="1">Qualified</td>
      <td align="center" rowspan="1" colspan="1">Qualified</td>
      <td align="center" rowspan="1" colspan="1">Qualified</td>
     </tr>
     <tr>
      <td align="left" rowspan="1" colspan="1">MDDR-like Rule</td>
      <td align="center" rowspan="1" colspan="1">Mid-structure</td>
      <td align="center" rowspan="1" colspan="1">Mid-structure</td>
      <td align="center" rowspan="1" colspan="1">Mid-structure</td>
     </tr>
    </tbody>
   </table>
  </div>
 </div>
 <p xmlns="http://www.w3.org/1999/xhtml">The values the permeability through human skin were −3.863 cm/h (EPI), −3.897 cm/h (EPIIS), and −3.045 cm/h (MAC); therefore, the compounds cannot be absorbed through human skin [
  <a rid="pone.0198476.ref053" ref-type="bibr" href="#pone.0198476.ref053">53</a>]. In the analysis of human intestinal absorption (HIA), one of the main parameters for new drug candidates, the analyzed alkaloids had values of 96.0% (EPI and EPIIS) and 97.5% (MAC). Some studies [
  <a rid="pone.0198476.ref054" ref-type="bibr" href="#pone.0198476.ref054">54</a>–
  <a rid="pone.0198476.ref055" ref-type="bibr" href="#pone.0198476.ref055">55</a>] have shown that values between 70% and 100% indicate good intestinal absorption.
 </p>
 <p xmlns="http://www.w3.org/1999/xhtml">The recommended parameters for the prediction of oral absorption of drugs use two permeability models, Caco-2 and MDCK cells. The values obtained for the alkaloids were considered intermediate [
  <a rid="pone.0198476.ref056" ref-type="bibr" href="#pone.0198476.ref056">56</a>]: 27.28 nm/s for MAC, 22.86 nm/s for EPIIS, and 21.83 nm/s for EPI in Caco-2 cells; and 15.79 nm/s for MAC, 16.04 nm/s for EPI, and 9.63 nm/s for EPIIS in MDCK cells.
 </p>
 <p xmlns="http://www.w3.org/1999/xhtml">None of the alkaloids inhibited P-glycoprotein, a protein responsible for the absorption, distribution, metabolism, and excretion of several different drugs [
  <a rid="pone.0198476.ref057" ref-type="bibr" href="#pone.0198476.ref057">57</a>]. In relation to solubility in water and pure water, the alkaloids EPIIS, ISOP, and PILO achieved higher values of 78,158.6 mg/L and 21,880 mg/L, respectively.
 </p>
 <p xmlns="http://www.w3.org/1999/xhtml">Data on the interaction with cytochrome P450 (CYP) protein indicated that all alkaloids were inhibitors of CYP 2C19, CYP 2C9, and CYP 3A4; this reduces the ability of these proteins to metabolize other drugs in the body, which suggests the possible accumulation of their potentiating metabolites to improve the pharmacological effect of these drugs. None of the alkaloids were found to be inhibitors of the CYP AD6 protein.</p>
 <p xmlns="http://www.w3.org/1999/xhtml">The characterization of mutagenicity by the Ames test indicated mutagenicity data for all tested alkaloids. However, in specific testing using TA100 and TA1535 cells, the results among the isomers were negative [
  <a rid="pone.0198476.ref058" ref-type="bibr" href="#pone.0198476.ref058">58</a>], and the alkaloids did not produce carcinogenicity in rats or mice.
 </p>
 <p xmlns="http://www.w3.org/1999/xhtml">All the alkaloids were suitable for drug classification by Lipinski’s rule (rule of five) and by the World Drug Index (WDI) as having a greater than 90% probability of solubility and permeability [
  <a rid="pone.0198476.ref059" ref-type="bibr" href="#pone.0198476.ref059">59</a>]. The Lipinski rule also has been applied [
  <a rid="pone.0198476.ref060" ref-type="bibr" href="#pone.0198476.ref060">60</a>] to evaluate ligands used in the formation of complexes with PNP. The isomeric alkaloids were classified as having higher binding affinity at 0.1 μM by the lead-like rule, except for MAC, which violated the rule [
  <a rid="pone.0198476.ref061" ref-type="bibr" href="#pone.0198476.ref061">61</a>]. In the CMC-like rule, all alkaloids were classified as qualified [
  <a rid="pone.0198476.ref062" ref-type="bibr" href="#pone.0198476.ref062">62</a>] and, for the MDDR-like rule, as an intermediate between a potential and non-potential drug [
  <a rid="pone.0198476.ref063" ref-type="bibr" href="#pone.0198476.ref063">63</a>].
 </p>
 <p xmlns="http://www.w3.org/1999/xhtml">As poor pharmacokinetic properties are important causes of late-stage failure in drug development, the reduction of these failures through the use of silicon tools such as ADME can lead to early predictions from the optimization of these properties [
  <a rid="pone.0198476.ref064" ref-type="bibr" href="#pone.0198476.ref064">64</a>].
 </p>
</sec>
